Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan-Dec:25:1076029618823288.
doi: 10.1177/1076029618823288.

Influence of Tumor Thrombus on Occurrence of Distant Venous Thromboembolism and Survival in Patients With Renal Cell Carcinoma After Surgery

Hyunkyung Park  1 , Chang Wook Jeong  2 , Hyeongdong Yuk  2 , Ja Hyeon Ku  2 , Hyeon Hoe Kim, Cheol Kwak  2 , Inho Kim  1   3
Affiliations

Influence of Tumor Thrombus on Occurrence of Distant Venous Thromboembolism and Survival in Patients With Renal Cell Carcinoma After Surgery

Hyunkyung Park et al. Clin Appl Thromb Hemost. 2019 Jan-Dec.

Abstract

Tumor thrombus is a unique characteristic of renal cell carcinoma (RCC). However, only a few studies have reported its clinical influence on the occurrence of venous thromboembolism (VTE). This study aimed to clarify the influence of tumor thrombus and other risk factors for VTE and to elucidate the impact of tumor thrombus on survival outcomes. We retrospectively reviewed data from patients with RCC who underwent radical or partial nephrectomy from September 1999 to August 2015 at Seoul National University Hospital. A total of 2762 patients were enrolled. The 1- and 5-year cumulative incidences of VTE were 0.5% ± 0.1% and 1.5% ± 0.3%, respectively. During a median follow-up of 39.0 months (95% confidence interval [CI], 37.1-41.0 months), deep vein thrombosis occurred in 13 patients and pulmonary embolism in 15 patients. Patients with tumor thrombus (diagnosed by surgical pathology findings) had a significantly higher incidence of VTE than those without thrombus (odds radio 8.160, 95% CI, 1.480-45.004). Older age (≥60 years) and higher preoperative C-reactive protein (>0.5 mg/dL) were also significant risk factors for VTE. Additionally, tumor thrombus was independently associated with worse progression-free survival (PFS) but not with overall survival (OS) in multivariable analysis (hazard ratio [HR] 1.916, 95% CI, 1.295-2.834 for PFS; HR 1.164, 95% CI, 0.755-1.793 for OS). In conclusion, the incidence of VTE was relatively low in patients who underwent surgery for RCC. Nevertheless, patients with tumor thrombus had an increased risk of VTE and should be closely monitored for VTE.

Keywords: renal cell carcinoma; risk factors; surgery; survival; venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Cumulative incidence of venous thromboembolism (VTE) in patients with renal cell carcinoma: (A) in all study patients, (B) according to the presence or absence of tumor thrombus (5-year cumulative incidence: 1.0% vs 10.4%, P < .001), (C) according to age (5-year cumulative incidence: 2.8% vs 0.1%, P < .001), and (D) according to C-reactive protein (5-year cumulative incidence: 6.0% vs 0.1%, P < .001).
Figure 2.
Figure 2.
Survival outcomes according to the presence or absence of tumor thrombus: (A) progression-free survival (5-year survival: 88.0% vs 37.4%, P < .001) and (B) overall survival (5-year survival: 90.0% vs 52.3%, P < .001).
See this image and copyright information in PMC

References

    1. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 suppl 1):I17–I21. - PubMed
    1. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ., III Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study. Arch Intern Med. 2000;160(6):809–815. - PubMed
    1. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–722. - PubMed
    1. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24(3):484–490. - PubMed
    1. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004;164(15):1653–1661. - PubMed